Nicola Smart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicola Smart has a total of 279 co-authors. Here are the top co-authors by number of shared publications:
- Andia Nicole Redpath
Department of Physiology, Anatomy & Genetics, Institute of Developmental and Regenerative Medicine, University of Oxford, United Kingdom (A.N.R., I.-E.L., L.H., Q.M.D., I.R.M., T.C., N.S.).
12 shared publications - Irina-Elena Lupu
Department of Physiology, Anatomy & Genetics, Institute of Developmental and Regenerative Medicine, University of Oxford, United Kingdom (A.N.R., I.-E.L., L.H., Q.M.D., I.R.M., T.C., N.S.).
5 shared publications - Joaquim Miguel Vieira
School of Cardiovascular and Metabolic Medicine and Sciences, British Heart Foundation Centre of Research Excellence, King's College London
5 shared publications Karina N. Dubé
UCL Institute of Child Health, London, United Kingdom
4 shared publicationsPaul R. Riley
British Heart Foundation Centre of Regenerative Medicine, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom
4 shared publications- Quang Minh Dang
Department of Physiology, Anatomy & Genetics, Institute of Developmental and Regenerative Medicine, University of Oxford, United Kingdom (A.N.R., I.-E.L., L.H., Q.M.D., I.R.M., T.C., N.S.).
4 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Springer Nature in Communications Biology
Distinct roles of the Lyve1 lineage in mouse heart development
The genetic mouse model Lyve1 Cre is widely used to study lymphatic endothelial cells, but its activity in the embryonic heart has not been comprehensively defined. Here we show that the Lyve1 lineage contributes to multiple cardiovascular cell types, including venous endothelium of the sinus venosus forming coronary vessels, endocardial cells generating complementary coronary territories and valve structures, lymphatic endothelial cells required for cardiac lymphatic development, and tissue-resident macrophages within the embryonic myocardium. Functional perturbations studies show that Notch1 gain-of-function in Lyve1 + lineages disrupts vascular development, whereas Prox1 deletion causes severe edema, blood-filled lymphatics, and perinatal lethality. Mid-gestation mutants exhibit underdeveloped blood-filled lymphatics despite intact blood vasculature, and by late gestation cardiac lymphatics are largely depleted. These findings reveal distinct cardiovascular roles of the Lyve1 lineage and establish Lyve1 Cre as a versatile but non-specific model, underscoring the need for careful interpretation when investigating heart development and regeneration.
- 21 October 2026
- Published by Springer Nature in Communications Biology
Open AccessDistinct roles of the Lyve1 lineage in mouse heart development
The genetic mouse model Lyve1 Cre is widely used to study lymphatic endothelial cells, but its activity in the embryonic heart has not been comprehensively defined. Here we show that the Lyve1 lineage contributes to multiple cardiovascular cell types, including venous endothelium of the sinus venosus forming coronary vessels, endocardial cells generating complementary coronary territories and valve structures, lymphatic endothelial cells required for cardiac lymphatic development, and tissue-resident macrophages within the embryonic myocardium. Functional perturbations studies show that Notch1 gain-of-function in Lyve1 + lineages disrupts vascular development, whereas Prox1 deletion causes severe edema, blood-filled lymphatics, and perinatal lethality. Mid-gestation mutants exhibit underdeveloped blood-filled lymphatics despite intact blood vasculature, and by late gestation cardiac lymphatics are largely depleted. These findings reveal distinct cardiovascular roles of the Lyve1 lineage and establish Lyve1 Cre as a versatile but non-specific model, underscoring the need for careful interpretation when investigating heart development and regeneration.
- Open Access
- 25 September 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (8)
Regulated HSPG Signaling Directs Epicardial Behavior to Support Cardiac Formation
BACKGROUND: Pathways controlling cardiac cell behavior share a common dependency on heparan sulfate proteoglycans (HSPGs), which tightly regulate signaling at extracellular locations. This signaling is essential for cardiac development, yet how HSPGs are regulated in the forming heart is unknown. The epicardium is a rich source of HSPG-dependent signaling and cellular progenitors. We hypothesized that extracellular heparan sulfate modifiers, 6- O -endosulfatases, orchestrate progenitor cell behavior to support cardiogenesis. METHODS: We used single-cell RNA sequencing, microscopy, and flow cytometry–based single-molecule RNA in situ hybridization (ISH) to systematically profile 6- O -endosulfatases and target HSPGs in the embryonic mouse heart. Subsequently, we utilized knockout and knockdown models that identified gene associations and a role for the main epicardial 6- O -endosulfatase isoform, Sulfatase (Sulf)1 . Transcriptional regulation of Sulf1 was assessed using assay for transposase-accessible chromatin (ATAC) and Cleavage Under Targets and Release Using Nuclease (CUT&RUN) with sequencing, luciferase assays, and siRNA, and the impact on epicardial cell behavior was confirmed in vivo and using in vitro functional assays. RESULTS: Despite identical function, we find that Sulf1 is expressed in the embryonic epicardium, while Sulfatase (Sulf)2 is expressed broadly throughout the myocardium. We show that epicardial SULF1 dynamically regulates HSPG sulfation to fine-tune the magnitude and duration of signaling to impact cell fate and cardiac morphogenesis. Single-cell genomics and lineage tracing studies reveal Sulf1 to be strongly coexpressed with key transcriptional regulator Wt1 (Wilms tumor 1) in the epicardium, with reduction of both coinciding with epithelial-to-mesenchymal transition and quiescence. CUT&RUN-seq revealed transcriptional control of Sulf1 by WT1, which directly impacts essential HSPG-dependent downstream signaling. Ligand-receptor interaction predictions and functional assays indicated that FGF (fibroblast growth factor)-2 and TGF-β (transforming growth factor β)–driven processes were governed by this regulatory interaction. CONCLUSIONS: Our study highlights, for the first time, essential fine-tuning of HSPG-dependent signaling to modulate key processes in heart formation, offering potential insights for therapeutically targeting congenital heart disease and enhancing epicardial proregenerative behaviors.
- 25 September 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (8)
Open AccessRegulated HSPG Signaling Directs Epicardial Behavior to Support Cardiac Formation
BACKGROUND: Pathways controlling cardiac cell behavior share a common dependency on heparan sulfate proteoglycans (HSPGs), which tightly regulate signaling at extracellular locations. This signaling is essential for cardiac development, yet how HSPGs are regulated in the forming heart is unknown. The epicardium is a rich source of HSPG-dependent signaling and cellular progenitors. We hypothesized that extracellular heparan sulfate modifiers, 6- O -endosulfatases, orchestrate progenitor cell behavior to support cardiogenesis. METHODS: We used single-cell RNA sequencing, microscopy, and flow cytometry–based single-molecule RNA in situ hybridization (ISH) to systematically profile 6- O -endosulfatases and target HSPGs in the embryonic mouse heart. Subsequently, we utilized knockout and knockdown models that identified gene associations and a role for the main epicardial 6- O -endosulfatase isoform, Sulfatase (Sulf)1 . Transcriptional regulation of Sulf1 was assessed using assay for transposase-accessible chromatin (ATAC) and Cleavage Under Targets and Release Using Nuclease (CUT&RUN) with sequencing, luciferase assays, and siRNA, and the impact on epicardial cell behavior was confirmed in vivo and using in vitro functional assays. RESULTS: Despite identical function, we find that Sulf1 is expressed in the embryonic epicardium, while Sulfatase (Sulf)2 is expressed broadly throughout the myocardium. We show that epicardial SULF1 dynamically regulates HSPG sulfation to fine-tune the magnitude and duration of signaling to impact cell fate and cardiac morphogenesis. Single-cell genomics and lineage tracing studies reveal Sulf1 to be strongly coexpressed with key transcriptional regulator Wt1 (Wilms tumor 1) in the epicardium, with reduction of both coinciding with epithelial-to-mesenchymal transition and quiescence. CUT&RUN-seq revealed transcriptional control of Sulf1 by WT1, which directly impacts essential HSPG-dependent downstream signaling. Ligand-receptor interaction predictions and functional assays indicated that FGF (fibroblast growth factor)-2 and TGF-β (transforming growth factor β)–driven processes were governed by this regulatory interaction. CONCLUSIONS: Our study highlights, for the first time, essential fine-tuning of HSPG-dependent signaling to modulate key processes in heart formation, offering potential insights for therapeutically targeting congenital heart disease and enhancing epicardial proregenerative behaviors.
- Open Access
- 3 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (34) , e17640
Organ‐Specific and Conserved Regulatory Logic Orchestrates Gene Expression in the Embryonic Mesothelium
The embryonic coelomic mesothelium acts as a critical progenitor hub during mammalian organogenesis, undergoing epithelial‐to‐mesenchymal transition (EMT) to drive vascular growth and parenchymal development in visceral organs. A prominent example is the epicardium, which plays an essential role during heart development. The principles of gene regulation in the coelomic mesothelium remain poorly defined. Specifically, it is unclear how cis‐regulatory elements, including enhancers, orchestrate the spatiotemporal patterns of gene expression required for mesothelial identity and function. Here, a multi‐omic approach was used to identify trans‐ and cis‐regulatory elements that regulate mesothelial gene expression in three organs: heart, lung, and pancreas. This analysis uncovers a cardiac‐specific regulatory circuit in which the transcription factor (TF) TBX20 selectively activates epicardial enhancers to orchestrate essential developmental programs. In contrast, TF MAF orchestrates pan‐mesothelial gene expression via conserved CREs, which are absent in non‐mesothelial lineages. Our integrated genomic analysis reveals MAF as a central custodian of mesothelial identity, a role underscored by its negative correlation with EMT, evolutionary conservation, and dynamic regulatory activity throughout development. Our work establishes a foundational blueprint of the gene regulatory landscape governing the coelomic mesothelium, defining both conserved principles and organ‐specific mechanisms of spatiotemporal gene expression during early mammalian development.
- 3 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (34) , e17640
Open AccessOrgan‐Specific and Conserved Regulatory Logic Orchestrates Gene Expression in the Embryonic Mesothelium
The embryonic coelomic mesothelium acts as a critical progenitor hub during mammalian organogenesis, undergoing epithelial‐to‐mesenchymal transition (EMT) to drive vascular growth and parenchymal development in visceral organs. A prominent example is the epicardium, which plays an essential role during heart development. The principles of gene regulation in the coelomic mesothelium remain poorly defined. Specifically, it is unclear how cis‐regulatory elements, including enhancers, orchestrate the spatiotemporal patterns of gene expression required for mesothelial identity and function. Here, a multi‐omic approach was used to identify trans‐ and cis‐regulatory elements that regulate mesothelial gene expression in three organs: heart, lung, and pancreas. This analysis uncovers a cardiac‐specific regulatory circuit in which the transcription factor (TF) TBX20 selectively activates epicardial enhancers to orchestrate essential developmental programs. In contrast, TF MAF orchestrates pan‐mesothelial gene expression via conserved CREs, which are absent in non‐mesothelial lineages. Our integrated genomic analysis reveals MAF as a central custodian of mesothelial identity, a role underscored by its negative correlation with EMT, evolutionary conservation, and dynamic regulatory activity throughout development. Our work establishes a foundational blueprint of the gene regulatory landscape governing the coelomic mesothelium, defining both conserved principles and organ‐specific mechanisms of spatiotemporal gene expression during early mammalian development.
- Open Access
- 1 March 2026
- Published by The Company of Biologists in Development
- Vol. 153 (5)
The RNA-binding protein SRSF3 controls epicardial formation by regulating splicing and proliferation
The epicardium is a fundamental regulator of cardiac development and regeneration, functioning to secrete essential growth factors and to produce epicardium-derived cells that contribute coronary mural cells and cardiac fibroblasts. The molecular mechanisms controlling epicardial formation have not been fully elucidated. In this study, we report that the RNA-binding protein SRSF3 is highly expressed in the embryonic proepicardium and epicardial layer. Deletion of Srsf3 from the murine proepicardium led to proliferative arrest, preventing proper epicardial formation. Induction of Srsf3 deletion after the proepicardial stage resulted in impaired epicardial proliferation and epicardium-derived cell formation. Single-cell RNA sequencing showed that SRSF3-depleted epicardial cells were eliminated; however, the surviving non-recombined cells upregulated Srsf3, became hyperproliferative and, remarkably, compensated for the early deficit. This unexpected finding attests to the importance of SRSF3 in controlling epicardial proliferation, and highlights the significant confounding effect of mosaic recombination on embryonic phenotyping. Mapping the SRSF3–RNA interaction network by endogenous irCLIP identified binding to major cell cycle regulators, including Ccnd1 and Map4k4, mediating both splicing and non-splicing roles. This research defines SRSF3 as an important regulator of epicardial formation and function.
- 1 March 2026
- Published by The Company of Biologists in Development
- Vol. 153 (5)
Open AccessThe RNA-binding protein SRSF3 controls epicardial formation by regulating splicing and proliferation
The epicardium is a fundamental regulator of cardiac development and regeneration, functioning to secrete essential growth factors and to produce epicardium-derived cells that contribute coronary mural cells and cardiac fibroblasts. The molecular mechanisms controlling epicardial formation have not been fully elucidated. In this study, we report that the RNA-binding protein SRSF3 is highly expressed in the embryonic proepicardium and epicardial layer. Deletion of Srsf3 from the murine proepicardium led to proliferative arrest, preventing proper epicardial formation. Induction of Srsf3 deletion after the proepicardial stage resulted in impaired epicardial proliferation and epicardium-derived cell formation. Single-cell RNA sequencing showed that SRSF3-depleted epicardial cells were eliminated; however, the surviving non-recombined cells upregulated Srsf3, became hyperproliferative and, remarkably, compensated for the early deficit. This unexpected finding attests to the importance of SRSF3 in controlling epicardial proliferation, and highlights the significant confounding effect of mosaic recombination on embryonic phenotyping. Mapping the SRSF3–RNA interaction network by endogenous irCLIP identified binding to major cell cycle regulators, including Ccnd1 and Map4k4, mediating both splicing and non-splicing roles. This research defines SRSF3 as an important regulator of epicardial formation and function.
- Open Access
Transcriptomic Analysis of Adult Mouse Cardiac Stromal Cells Using Single-Cell qRT-PCR
Fate-mapping studies have challenged the longstanding view of the adult mammalian heart as a post-mitotic organ, suggesting limited cardiomyocyte renewal. This has spurred efforts to determine whether selected cardiac stromal cells have regenerative potential; however, their contribution to cardiac regeneration has been found to be minimal compared with that of cardiomyocyte proliferation. Despite this, transplantation of some cardiac stromal cell populations has shown therapeutic potential through paracrine signalling. The identity of the paracrine-active stromal cell populations remains unclear due to overlapping characteristics with other cardiac stromal cell populations, such as fibroblasts, mesenchymal cells, and pericytes. This study sought to clarify the transcriptional identity and heterogeneity of adult mouse cardiac stromal cells by developing a cardiac collagenase–trypsin protocol and comparing it to the established method for isolating cardiosphere-derived cells (CDCs). This novel protocol resulted in a higher cell yield and shorter expansion time, and the resulting cells showed superior survival under serum starvation compared to commercially acquired cardiac fibroblasts (CFs). Single-cell qRT-PCR analysis revealed that collagenase–trypsin cells (CTs) and CDCs share similar gene expression profiles, distinct from those of CFs. Notably, CTs exhibited higher expression of Tcf21 and lower expression of Tbx5, suggesting an epicardial-derived fibroblast phenotype, whereas Tbx5 was enriched in CDCs and CFs, reflecting heterogeneity within the cardiac fibroblast compartment. This study offers insights into the complex identity of cardiac stromal cells and concludes that CTs closely resemble CDCs but can be generated more rapidly, making them a robust and efficient source of paracrine-active cardiac stromal cells.
Open AccessTranscriptomic Analysis of Adult Mouse Cardiac Stromal Cells Using Single-Cell qRT-PCR
Fate-mapping studies have challenged the longstanding view of the adult mammalian heart as a post-mitotic organ, suggesting limited cardiomyocyte renewal. This has spurred efforts to determine whether selected cardiac stromal cells have regenerative potential; however, their contribution to cardiac regeneration has been found to be minimal compared with that of cardiomyocyte proliferation. Despite this, transplantation of some cardiac stromal cell populations has shown therapeutic potential through paracrine signalling. The identity of the paracrine-active stromal cell populations remains unclear due to overlapping characteristics with other cardiac stromal cell populations, such as fibroblasts, mesenchymal cells, and pericytes. This study sought to clarify the transcriptional identity and heterogeneity of adult mouse cardiac stromal cells by developing a cardiac collagenase–trypsin protocol and comparing it to the established method for isolating cardiosphere-derived cells (CDCs). This novel protocol resulted in a higher cell yield and shorter expansion time, and the resulting cells showed superior survival under serum starvation compared to commercially acquired cardiac fibroblasts (CFs). Single-cell qRT-PCR analysis revealed that collagenase–trypsin cells (CTs) and CDCs share similar gene expression profiles, distinct from those of CFs. Notably, CTs exhibited higher expression of Tcf21 and lower expression of Tbx5, suggesting an epicardial-derived fibroblast phenotype, whereas Tbx5 was enriched in CDCs and CFs, reflecting heterogeneity within the cardiac fibroblast compartment. This study offers insights into the complex identity of cardiac stromal cells and concludes that CTs closely resemble CDCs but can be generated more rapidly, making them a robust and efficient source of paracrine-active cardiac stromal cells.
- Open Access
Distinct roles of the Lyve1 lineage in heart development
Lyve1Cre is widely used to study lymphatic endothelial cells, but its activity in the embryonic heart has not been comprehensively defined. Here we show that the Lyve1 lineage contributes to multiple cardiovascular cell types, including venous endothelium of the sinus venosus forming coronary vessels, endocardial cells generating complementary coronary territories and valve structures, lymphatic endothelial cells required for cardiac lymphatic development, and tissue-resident macrophages within the embryonic myocardium. Functional perturbations demonstrated that Notch1 gain-of-function in Lyve1+ lineages disrupted vascular development, while Prox1 deletion caused severe edema, blood-filled lymphatics, and perinatal lethality. Mid-gestation mutants exhibited underdeveloped, blood-filled lymphatics despite intact blood vasculature, and by late gestation cardiac lymphatics were depleted. These findings reveal distinct cardiovascular roles of the Lyve1 lineage and establish Lyve1Cre as a versatile but non-specific tool, underscoring the need for careful interpretation when investigating heart development and regenerative processes.
Open AccessDistinct roles of the Lyve1 lineage in heart development
Lyve1Cre is widely used to study lymphatic endothelial cells, but its activity in the embryonic heart has not been comprehensively defined. Here we show that the Lyve1 lineage contributes to multiple cardiovascular cell types, including venous endothelium of the sinus venosus forming coronary vessels, endocardial cells generating complementary coronary territories and valve structures, lymphatic endothelial cells required for cardiac lymphatic development, and tissue-resident macrophages within the embryonic myocardium. Functional perturbations demonstrated that Notch1 gain-of-function in Lyve1+ lineages disrupted vascular development, while Prox1 deletion caused severe edema, blood-filled lymphatics, and perinatal lethality. Mid-gestation mutants exhibited underdeveloped, blood-filled lymphatics despite intact blood vasculature, and by late gestation cardiac lymphatics were depleted. These findings reveal distinct cardiovascular roles of the Lyve1 lineage and establish Lyve1Cre as a versatile but non-specific tool, underscoring the need for careful interpretation when investigating heart development and regenerative processes.
- 20 December 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (18) , 2809-2812
Mechanotransduction as an emerging pathophysiological determinant of cardiovascular diseases
- 20 December 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (18) , 2809-2812
Mechanotransduction as an emerging pathophysiological determinant of cardiovascular diseases
- Open Access
Bridging the Translational Gap: Rethinking Smooth Muscle Cell Plasticity in Atherosclerosis Through Human-Relevant In Vitro Models
While vascular smooth muscle cell (SMC) plasticity is increasingly recognised as a critical driver of atherosclerosis progression, most mechanistic insights derive from murine models that fail to fully capture the diversity and complexity of human SMC phenotypes. This creates a translational gap in our understanding of disease-relevant cell states. Human single-cell and genetic studies reveal a broader spectrum of SMC phenotypes, many of which remain uncaptured by existing experimental models. In this review, we argue that better human in vitro models, when critically assessed and integrated with omics data from human disease, can help bridge this gap. We examine how different in vitro systems, from simple monocultures to advanced co-culture and 3D platforms, can model human SMC plasticity, and how benchmarking against human single-cell and multi-omics data can guide model selection, validation, and refinement.
Open AccessBridging the Translational Gap: Rethinking Smooth Muscle Cell Plasticity in Atherosclerosis Through Human-Relevant In Vitro Models
While vascular smooth muscle cell (SMC) plasticity is increasingly recognised as a critical driver of atherosclerosis progression, most mechanistic insights derive from murine models that fail to fully capture the diversity and complexity of human SMC phenotypes. This creates a translational gap in our understanding of disease-relevant cell states. Human single-cell and genetic studies reveal a broader spectrum of SMC phenotypes, many of which remain uncaptured by existing experimental models. In this review, we argue that better human in vitro models, when critically assessed and integrated with omics data from human disease, can help bridge this gap. We examine how different in vitro systems, from simple monocultures to advanced co-culture and 3D platforms, can model human SMC plasticity, and how benchmarking against human single-cell and multi-omics data can guide model selection, validation, and refinement.
- Open Access
Precision Targeting of Troponin I Phosphorylation Prevents Diastolic Dysfunction while Preserving Systolic Performance
Background: Defective cardiac relaxation (diastolic dysfunction) is prevalent in heart failure, particularly in the context of diabetes, obesity, hypertension, and ageing, and is associated with increased mortality. Yet there is no available treatment that directly targets this abnormal relaxation. Phosphorylation of troponin I by cAMP-dependent protein kinase A (PKA) promotes relaxation, but global PKA activation has widespread, undesirable effects. Here we investigated whether selectively enhancing troponin I phosphorylation could improve relaxation without engaging the broader PKA signalling network. Methods: To resolve cAMP signalling at subcellular scales, we combined real-time cAMP measurements with FRET-based genetically encoded reporters targeted to defined nanodomains, alongside biochemical and genetic approaches. Protein–protein interaction surfaces were mapped using peptide-array technology, which guided the design of a disruptor peptide to displace specific interactions. The peptide’s effects on cardiomyocyte function were assessed in vitro using rodent and human cardiomyocytes with biochemical assays, real-time imaging, and work-loop analysis. In vivo effects were evaluated through echocardiography and haemodynamic measurements. Results: We identified a previously unrecognized regulatory mechanism in which the cAMP-hydrolyzing enzyme PDE4D9 interacts with troponin I and restricts local cAMP levels within a nanometre-scale domain, thereby selectively controlling troponin I phosphorylation. We found that PDE4D9–troponin I association is markedly increased in cardiac disease in both rodents and humans. A peptide that displaces PDE4D9 from troponin I in a mouse model of heart failure selectively enhances troponin I phosphorylation, accelerates cardiomyocyte relaxation, and prevents diastolic dysfunction, without compromising systolic contractility. Conclusions: These findings reveal a highly specific regulatory nanodomain governing troponin I phosphorylation and points to a first-in-class, mechanism-based therapeutic strategy with the potential to address a major unmet contributor to heart failure. Clinical Perspective: What Is New?: We identify a previously unrecognized, nanometre-scale regulatory mechanism in which PDE4D9 binds troponin I to locally suppress cAMP, limit troponin I phosphorylation and attenuate relaxation. We demonstrate that this mechanism becomes maladaptive in disease: PDE4D9–troponin I interaction is markedly upregulated in failing hearts in both rodents and humans, which can mechanistically explain the impaired cardiac relaxation. We show that this interaction is druggable: a rationally designed peptide can selectively displace PDE4D9, restore localized cAMP–PKA signalling, and normalize myocardial relaxation without global cAMP perturbation. Displacement of PDE4D9 from TPNI improves relaxation with no impact on the calcium transient amplitude and without adversely affecting systolic output and cardiac reserve. What Are the Clinical Implications?: Diastolic dysfunction, a major cause of heart failure with no targeted treatments, may be amenable to therapies that modulate cAMP signalling with subcellular precision rather than global pathway modulation. Selective disruption of PDE4D9–troponin I binding offers a mechanism-based approach with potential to restore diastolic function while minimizing off-target effects typical of GPCR-directed therapies. By enhancing relaxation while preserving systolic function and cardiac reserve, this approach may overcome limitations of myofilament-targeted therapies currently under evaluation for diastolic dysfunction that exhibit negative inotropic effects. More broadly, this work establishes a platform for targeting localized signalling domains, a concept that may extend beyond cardiovascular disease to other pathological conditions in which dysregulated cAMP contributes to dysfunction.
Open AccessPrecision Targeting of Troponin I Phosphorylation Prevents Diastolic Dysfunction while Preserving Systolic Performance
Background: Defective cardiac relaxation (diastolic dysfunction) is prevalent in heart failure, particularly in the context of diabetes, obesity, hypertension, and ageing, and is associated with increased mortality. Yet there is no available treatment that directly targets this abnormal relaxation. Phosphorylation of troponin I by cAMP-dependent protein kinase A (PKA) promotes relaxation, but global PKA activation has widespread, undesirable effects. Here we investigated whether selectively enhancing troponin I phosphorylation could improve relaxation without engaging the broader PKA signalling network. Methods: To resolve cAMP signalling at subcellular scales, we combined real-time cAMP measurements with FRET-based genetically encoded reporters targeted to defined nanodomains, alongside biochemical and genetic approaches. Protein–protein interaction surfaces were mapped using peptide-array technology, which guided the design of a disruptor peptide to displace specific interactions. The peptide’s effects on cardiomyocyte function were assessed in vitro using rodent and human cardiomyocytes with biochemical assays, real-time imaging, and work-loop analysis. In vivo effects were evaluated through echocardiography and haemodynamic measurements. Results: We identified a previously unrecognized regulatory mechanism in which the cAMP-hydrolyzing enzyme PDE4D9 interacts with troponin I and restricts local cAMP levels within a nanometre-scale domain, thereby selectively controlling troponin I phosphorylation. We found that PDE4D9–troponin I association is markedly increased in cardiac disease in both rodents and humans. A peptide that displaces PDE4D9 from troponin I in a mouse model of heart failure selectively enhances troponin I phosphorylation, accelerates cardiomyocyte relaxation, and prevents diastolic dysfunction, without compromising systolic contractility. Conclusions: These findings reveal a highly specific regulatory nanodomain governing troponin I phosphorylation and points to a first-in-class, mechanism-based therapeutic strategy with the potential to address a major unmet contributor to heart failure. Clinical Perspective: What Is New?: We identify a previously unrecognized, nanometre-scale regulatory mechanism in which PDE4D9 binds troponin I to locally suppress cAMP, limit troponin I phosphorylation and attenuate relaxation. We demonstrate that this mechanism becomes maladaptive in disease: PDE4D9–troponin I interaction is markedly upregulated in failing hearts in both rodents and humans, which can mechanistically explain the impaired cardiac relaxation. We show that this interaction is druggable: a rationally designed peptide can selectively displace PDE4D9, restore localized cAMP–PKA signalling, and normalize myocardial relaxation without global cAMP perturbation. Displacement of PDE4D9 from TPNI improves relaxation with no impact on the calcium transient amplitude and without adversely affecting systolic output and cardiac reserve. What Are the Clinical Implications?: Diastolic dysfunction, a major cause of heart failure with no targeted treatments, may be amenable to therapies that modulate cAMP signalling with subcellular precision rather than global pathway modulation. Selective disruption of PDE4D9–troponin I binding offers a mechanism-based approach with potential to restore diastolic function while minimizing off-target effects typical of GPCR-directed therapies. By enhancing relaxation while preserving systolic function and cardiac reserve, this approach may overcome limitations of myofilament-targeted therapies currently under evaluation for diastolic dysfunction that exhibit negative inotropic effects. More broadly, this work establishes a platform for targeting localized signalling domains, a concept that may extend beyond cardiovascular disease to other pathological conditions in which dysregulated cAMP contributes to dysfunction.
- 15 August 2025
- Published by Wolters Kluwer Health in Circulation Research
Spatio-Temporal Proliferative Heterogeneity of Intra-Organ Endothelial Cells
BACKGROUND: Blood vessels play a crucial role in supplying tissues with oxygen and nutrients. The maintenance of normal blood vessel number and integrity requires a continuous supply of new endothelial cells (ECs) through self-replication. While it is established that ECs across different tissues exhibit heterogeneity in molecular signatures and regenerative capacities, the extent of proliferation heterogeneity among ECs within the same organ or tissue remains largely unexplored. METHODS: An EC-specific proliferation tracing system was developed to investigate the proliferative heterogeneity of ECs in the heart, liver, and lung. A combination of RNA sequencing, spatial transcriptomics, and single-cell RNA sequencing was used to uncover the underlying mechanisms of this heterogeneity. An MAPK signaling inhibitor was administered in vivo to functionally assess pathway involvement. Injury models, including transverse aortic constriction, myocardial infarction, partial hepatectomy, and pneumonectomy, were utilized to assess stress-induced EC proliferation. RESULTS: EC proliferation exhibits marked intraorgan heterogeneity. In the heart, ECs in the upper part of the ventricular septum, the superior-inner left ventricle wall, and the apex showed elevated proliferation. In the liver, E-CAD (e-cadherin)±1 liver sinusoidal EC displayed a distinct proliferative advantage. In the lung, PLVAP (plasma membrane vesicle–associated protein) + ECs renew more actively than CAR4 (carbonic anhydrase 4) + ECs. Multiomics analysis revealed regional transcription diversity. In vivo MAPK inhibition confirmed its role in regulating EC proliferative heterogeneity. CONCLUSIONS: This study uncovers regional and subtype-specific proliferation in the heart, liver, and lung, driven by distinct gene expression programs. These findings highlight the spatial and functional diversity of microvascular ECs and offer a framework for developing organ-specific vascular regenerative strategies.
- 15 August 2025
- Published by Wolters Kluwer Health in Circulation Research
Spatio-Temporal Proliferative Heterogeneity of Intra-Organ Endothelial Cells
BACKGROUND: Blood vessels play a crucial role in supplying tissues with oxygen and nutrients. The maintenance of normal blood vessel number and integrity requires a continuous supply of new endothelial cells (ECs) through self-replication. While it is established that ECs across different tissues exhibit heterogeneity in molecular signatures and regenerative capacities, the extent of proliferation heterogeneity among ECs within the same organ or tissue remains largely unexplored. METHODS: An EC-specific proliferation tracing system was developed to investigate the proliferative heterogeneity of ECs in the heart, liver, and lung. A combination of RNA sequencing, spatial transcriptomics, and single-cell RNA sequencing was used to uncover the underlying mechanisms of this heterogeneity. An MAPK signaling inhibitor was administered in vivo to functionally assess pathway involvement. Injury models, including transverse aortic constriction, myocardial infarction, partial hepatectomy, and pneumonectomy, were utilized to assess stress-induced EC proliferation. RESULTS: EC proliferation exhibits marked intraorgan heterogeneity. In the heart, ECs in the upper part of the ventricular septum, the superior-inner left ventricle wall, and the apex showed elevated proliferation. In the liver, E-CAD (e-cadherin)±1 liver sinusoidal EC displayed a distinct proliferative advantage. In the lung, PLVAP (plasma membrane vesicle–associated protein) + ECs renew more actively than CAR4 (carbonic anhydrase 4) + ECs. Multiomics analysis revealed regional transcription diversity. In vivo MAPK inhibition confirmed its role in regulating EC proliferative heterogeneity. CONCLUSIONS: This study uncovers regional and subtype-specific proliferation in the heart, liver, and lung, driven by distinct gene expression programs. These findings highlight the spatial and functional diversity of microvascular ECs and offer a framework for developing organ-specific vascular regenerative strategies.